Zimbabwe has rejected a substantial US healthcare agreement worth $367m (£272m) spanning five years because of Washington's request for confidential biological samples.
This rejection was revealed following a internal memorandum from December was leaked, indicating that Head of State Emmerson Mnangagwa felt the arrangement was "unbalanced".
A government representative later explained that the US was demanding access to health data for research and profit while was not willing to share the benefits from future treatments.
"We must now begin the challenging and unfortunate task of ending our support in Zimbabwe," remarked American envoy to Zimbabwe Pamela Tremont publicly.
Her embassy indicated the US had donated more than $1.9bn for health programmes to Zimbabwe during the past twenty years.
A doctors' association in Zimbabwe has appealed for continued dialogue to reach a deal suitable to all parties so the nation's critical HIV programme can continue.
Wider Implications
This rejection follows a comparable case in Kenya, where a high court blocked a related health funding agreement following legal challenges were raised about the safety of citizens' medical information.
After resuming the presidency last year, US President Donald Trump has slashed foreign aid and closed the key foreign aid agency.
USAID had overseen assistance for the US government, but Trump claimed its spending was "wasteful" and his administration was pursuing direct bilateral agreements to boost openness and accountability.
Based on reports, 16 nations in Africa have to date signed these new agreements, constituting more than $18.3bn in new funding.
Specifics of the Rejected Deal
This assistance for Zimbabwe was intended to gone towards "combating HIV/Aids, tuberculosis, malaria, healthcare for mothers and children, and preparing for epidemics".
"We believe this partnership could have provided immense benefits for Zimbabwean communities, especially the 1.2 million presently receiving HIV treatment through American-funded programmes," Tremont commented.
However, government spokesperson Nick Mangwana argued the arrangement was "unequal".
"Our nation was requested to provide its biological resources and data indefinitely, without any equivalent guarantee of benefiting from any scientific breakthroughs – such as vaccines, diagnostics, or treatments – that might be developed from that provided information," Mangwana explained.
"Put simply, our country would supply the raw materials for scientific discovery without any certainty that the final treatments would be available to our citizens if a future pandemic arise."
National Interest and Global Health
He also said that the US's withdrawal from the global health body and its pursuit of one-on-one deals were undermining systems already set up through the global organization.
Mangwana gave as an example its Pathogen Access and Benefit Sharing system designed to deal with future pandemics.
"This mechanism is designed to guarantee that when a country provides its information, the benefits – including medicines and cures – are distributed fairly, not monopolised solely by those with the funds to develop them."
Zimbabwe's reservations regarding the US deal "must not be interpreted as anti-American sentiment," he added.
"We encourage ongoing dialogue with our US partners on how future co-operation might be arranged in a way that honours the independence and interests of each country."
Health Experts Response
The Zimbabwe College of Public Health Physicians (ZCPHP) stated it recognised the government's concerns, but recommended that negotiations must proceed since a large portion of the nation's HIV programmes depended on foreign aid.
"In cases where technical issues exist, including those relating to data governance or implementation frameworks, these can often be resolved through technical clarification and mutually agreed protections," the group said.
The situation underscores the ongoing tensions between accepting vital international aid and protecting local interests in an ever more data-driven world.